0.8687

1.34% -0.0176

Gossamer Bio Inc (GOSS)

Overview News Price History Option Chain Financials Discussions Forecast

Gossamer Bio Inc stock is traded at $0.8687, with a volume of 303.45K. It is down -1.34% in the last 24 hours and down -18.28% over the past month. Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.

Previous Close:

$0.8863

Open:

$0.898

24h Volume:

303.45K

Relative Volume:

0.37

Market Cap:

$200.46M

Revenue:

Net Income/Loss:

$-179.82M

P/E Ratio:

-0.3931

EPS:

-2.21

Net Cash Flow:

$-159.16M

1W Performance:

-4.36%

1M Performance:

-18.28%

6M Performance:

+18.16%

1Y Performance:

+53.30%

1-Day Range:

$0.86

$0.898

1-Week Range:

$0.7789

$0.9325

52-Week Range:

$0.494

$1.60

Gossamer Bio Inc Stock (GOSS) Company Profile

Name

Gossamer Bio Inc

Sector

Healthcare (1181)

Industry

Biotechnology (680)

Phone

(858) 922-0718

Address

3013 SCIENCE PARK, SAN DIEGO, CA

Employee

135

Twitter

@GossamerBio

Next Earnings Date

2024-11-07

Latest SEC Filings

GOSS's Discussions on Twitter

Gossamer Bio Inc Stock (GOSS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-25-24	Initiated	Oppenheimer	Outperform
Apr-05-24	Resumed	Wedbush	Outperform
Jul-27-23	Downgrade	UBS	Buy → Neutral
Mar-07-23	Downgrade	Raymond James	Outperform → Mkt Perform
Mar-01-23	Initiated	Guggenheim	Neutral
Dec-07-22	Downgrade	Barclays	Overweight → Equal Weight
Dec-07-22	Downgrade	JP Morgan	Neutral → Underweight
Dec-07-22	Downgrade	SMBC Nikko	Outperform → Neutral
Oct-20-22	Initiated	Goldman	Buy
Sep-21-22	Initiated	JP Morgan	Neutral
Sep-19-22	Initiated	Wedbush	Outperform
Apr-18-22	Initiated	Raymond James	Outperform
Apr-06-22	Initiated	UBS	Buy
Jan-10-22	Upgrade	SMBC Nikko	Neutral → Outperform
Nov-09-21	Resumed	Cantor Fitzgerald	Overweight
Sep-21-21	Resumed	Piper Sandler	Overweight
Jun-29-20	Initiated	H.C. Wainwright	Buy
Apr-22-20	Initiated	Piper Sandler	Overweight
Feb-27-20	Initiated	Barclays	Overweight
Dec-03-19	Resumed	BofA/Merrill	Buy
Oct-30-19	Initiated	Berenberg	Buy
Mar-05-19	Initiated	Barclays	Overweight
Mar-05-19	Initiated	BofA/Merrill	Buy
Mar-05-19	Initiated	Evercore ISI	Outperform
Mar-05-19	Initiated	SVB Leerink	Outperform

View All

Gossamer Bio Inc Stock (GOSS) Latest News

Oct 30, 2024

Gossamer Bio, Inc. (NASDAQ:GOSS) Short Interest Update - MarketBeat

Oct 30, 2024

Gossamer Bio, Inc. (NASDAQ:GOSS) Sees Large Decline in Short Interest - Defense World

Oct 30, 2024

Oct 28, 2024

3 US Penny Stocks With Market Caps Under $900M To Consider - Simply Wall St

Oct 28, 2024

Oct 18, 2024

Gossamer Bio, Inc. (NASDAQ:GOSS) Shares Bought by The Manufacturers Life Insurance Company - Defense World

Oct 18, 2024

Oct 17, 2024

Hypertension Clinical Trials 2024: FDA Approvals, Medication, Therapies, MOA, ROA, Companies by DelveInsight | Quantum Genomics, CinCor Pharma, Mineralys Therapeutics, Alnylam Therapeutics, Novartis - The Globe and Mail

Oct 17, 2024

Oct 15, 2024

It makes sense and dollars to buy Gossamer Bio Inc (GOSS) stock - SETE News

Oct 15, 2024

Oct 14, 2024

Financial Fitness Check: Examining Gossamer Bio Inc (GOSS)’s Key Ratios - The Dwinnex

Oct 14, 2024